Western blot of U2OS wild-type and
ATM KO cells, probed using the indicated antibodies. (
B) Aggregated (silver stain) and whole-cell lysate (WCL; Coomassie) fractions of HEK293 wild-type and
ATM KO cells. Three independent biological repeats were loaded on one gel and stained in-gel. WCL fractions were also subjected to Western blotting and probed using the indicated antibodies. (
C) Quantification of (
A). Circles depict individual experiments. Two-tailed Student’s
t-test. (
D) Experimental outline of
Figure 1C and E. (
E) Aggregated (silver stain) and WCL (Coomassie) fractions of U2OS cells treated with increasing doses of camptothecin (CPT) (0.2, 0.4, 0.6 μM). n = 2. (
F) Aggregated (silver stain) and WCL (Coomassie) fractions of HEK293T cells treated transiently with CPT (40 nM) following the same experimental set-up as in (
D). PARP inhibitor (4 μM, see also Materials and methods) was added during the recovery period. (
G) Quantification of (
F). Circles depict individual experiments. Two-tailed Student’s
t-test with Bonferroni correction. In (
C) and (
G), red lines indicate the mean.